SCHEMBL20073769

SCHEMBL20073769

CSc1cc(C2CC2)ccc1N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.38
HDAC2 Q92769 5/20 0.38
HDAC3 O15379 1/20 0.38
NPC1 O15118 2/20 0.35
RAB9A P51151 1/20 0.35
ESR2 Q92731 3/20 0.34
BACE1 P56817 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
QDPR P09417 2/20 0.33
KCNH2 Q12809 1/20 0.31
HRH4 Q9H3N8 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
G6PD P11413 1/20 0.31
IDE P14735 1/20 0.31
NOS3 P29474 1/20 0.30
NOS1 P29475 1/20 0.30
NOS2 P35228 1/20 0.30
KHK P50053 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20073632 0.93 BACE1 (0.38) HDAC1HDAC2HDAC3NPC1RAB9A
SCHEMBL11896445 0.91 BACE1 (0.44) HDAC1HDAC2HDAC3BACE1MEN1
SCHEMBL20150185 0.88 HTR1D (0.36) HDAC1HDAC2HDAC3NPC1RAB9A
SCHEMBL843886 0.74 HDAC1 (0.44) HDAC1HDAC2HDAC3ESR2BACE1
SCHEMBL16950468 0.74 ALDH1A1 (0.38) ESR2QDPRKCNH2KHKHTR2C
SCHEMBL19062075 0.74 CYP3A4 (0.48) HDAC1HDAC2HDAC3ESR2BACE1
SCHEMBL16950466 0.73 ESR2 (0.33) ESR2QDPRKHKHTR2C
SCHEMBL5165904 0.72 CASP1 (0.44) NPC1RAB9AMEN1KMT2AAPOBEC3G
SCHEMBL6935620 0.71 HDAC1 (0.41) HDAC1HDAC2HDAC3ESR2BACE1
SCHEMBL20150176 0.70 MAPT (0.37) RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-03-10 US disclosed
US-11220508-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2022-01-11 US disclosed
US-11174265-B2 2021-11-16 US disclosed
US-20210230163-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-07-29 US disclosed
EP-3848370-A2 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2021-07-14 EP disclosed
US-10793574-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-10-06 US disclosed
US-20190284194-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-09-19 US disclosed
US-10323036-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2019-06-18 US disclosed
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 US disclosed
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 US disclosed
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-17 US disclosed
WO-2018075937-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-26 WO disclosed
WO-2018071794-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220508-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885
US-10793574-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885
US-10323036-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885
US-20210230163-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885
US-20180134700-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885
US-20190284194-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885
US-11174265-B2 TYK2, JAK2, JAK1 HDAC1 1463/4885HDAC2 569/4885HDAC3 984/4885
US-20180155349-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885
US-20220073527-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HDAC1 2265/4885HDAC2 926/4885HDAC3 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.